Novavax, PATH deal

Novavax and not-for-profit PATH said they are continuing their 2012 deal to develop Novavax's RSV-F vaccine against respiratory syncytial virus (RSV) for maternal immunization in low-resource countries. PATH will now provide Novavax with about $3.5 million to support an ongoing Phase II trial of the vaccine, which is directed against the viral fusion F protein and formulated in virus-like particles (VLPs).

Under the 2012 deal, Novavax retains worldwide rights to commercialize the product and committed to make the vaccine affordable and available in low-resource countries. The partners could not be reached for details (see BioCentury, July 23, 2012 & Oct. 14, 2013). ...